Peter Goss Discusses FDA Approval of New Implant for Opioid Addiction Treatment

Peter J. Goss was interviewed by Law360 for an article analyzing the FDA’s recent approval of an implantable version of an opioid addiction drug, Probuphine.  (“FDA’s Opioid Implant Nod Shows Pressure To Curb Addiction,” available to Law360 subscribers here.)  Goss noted that the FDA has been under pressure to curb the opioid abuse epidemic, and that the approval of the Probuphine implant adds “one more tool … to the overall toolkit physicians will have for treating opioid addicts.” 

Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented global pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence, products liability, and legal developments of interest to his clients.

Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for several Fortune 500 companies. The firm has extensive experience in class action defense, commercial litigation, food industry defense, labor and employment, and products liability. The firm has represented corporate clients in state and federal courts throughout the country and in several foreign jurisdictions.

For more information about Blackwell Burke P.A. or Mr. Goss, please contact Kandy Branch at 612-343-3235 or kbranch@blackwellburke.com